AI · Energy
KRW 42 trillion investment over next 10 years in AI defined vehicles with Level 4 or higher automation, manufacturing AI, aerospace and next-generation energy infrastructure
⋯ AI DVs: Establishing an AI DV manufacturing hub including the Ulsan EV plant
⋯ Core components cluster: Build production lines for battery system, motors/controllers and thermal management system
⋯ AI-based manufacturing: Create a virtuous cycle of manufacturing innovation led by physical AI and high-quality data
⋯ Future aviation & space: Develop core technologies for air mobility and lunar rovers
⋯ Energy infrastructure innovation: Expand SMR and water electrolysis infrastructure
MOU signed with government and local authorities to coordinate industrial ecosystem development
Strengthening future competitiveness and growth through comprehensive advanced industry investments in Korea's southeastern region
Jul 3 · 07:00·Hyundai Motor Company
Automotive · Education
In conjunction with the Ministry of Sustainability and the Environment’s (MSE) Go Green SG 2026, Hackathon was hosted by HMGICS and Hyundai CRADLE Singapore in partnership with Temasek Foundation, with support from the National University of Singapore (NUS)
Fifth edition rallied the largest cohort of 91 students from nine local and international schools to date to co-create climate adaptation solutions in support of the Year of Climate Adaptation
HMGICS and Hyundai CRADLE Singapore are committed to growing alongside Singapore by empowering and nurturing future-ready youths through their annual CSR Hackathon programme
Jun 4 · 09:00·Hyundai Motor Company
Healthcare · Food & drink
Berlin, May 19, 2026 – Bayer today announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare have accepted the company’s New Drug Applications (NDA) for its investigational Factor XIa (FXIa) inhibitor, asundexian, for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). In addition, the U.S. FDA granted asundexian Priority Review designation.
Approximately 12 million people experience a stroke every year.3 Of those who survive a stroke, approximately 1 in 10 will have another stroke within 1 year, even with available secondary stroke prevention strategies.1
“The acceptances of submissions in key markets represent another milestone in the development of asundexian and in our commitment to secondary stroke care. More than 90 million people worldwide are living with the consequences of a stroke, highlighting its significant impact on public health,” said Christian Rommel, Ph.D., Head of Research and Development at Bayer`s Pharmaceuticals Division. “We are collaborating with health authorities to advance the approval process.”
Bayer is continuing to submit applications for marketing authorization for asundexian to other health authorities globally. China’s Center of Drug Evaluation has also recently accepted Bayer’s marketing authorization application for asundexian and granted it Priority Review designation.
About OCEANIC-STROKE
The Phase III OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary efficacy endpoint was time to ischemic stroke; the primary safety endpoint was ISTH major bleeding. The full results from OCEANIC-STROKE have recently been published in The New England Journal of Medicine.
The applications to the U.S. FDA and to Japan’s Ministry of Health, Labour and Welfare are based on positive data from the Phase III OCEANIC-STROKE study. The study found that asundexian 50 mg, significantly reduced ischemic stroke by 26 percent in patients after a non-cardioembolic ischemic stroke or high-risk TIA compared to placebo, both in combination with antiplatelet therapy, with no increase in ISTH (International Society on Thrombosis and Hemostasis) major bleeding.
About FXIa Inhibitors and Asundexian
Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa is thought to contribute to the formation of pathological thrombus growth and vessel blockage. However, FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury.
Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication.
About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine
Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. The company has set a clear focus on developing therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on LinkedIn: Bayer | Pharmaceuticals
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
1 Kolmos M, Christoffersen L, Kruuse C. Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2021;30(8):105935.
2 U.S. Food and Drug Administration. Priority Review. 2018. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review. Last accessed: May 2026.
3 Feigin VL, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022;17(1):18-29.
May 19 · 06:29·Bayer
Energy · Automotive
Hyundai Motor Group announces a multi-year partnership on hydrogen mobility solutions with the Georgia Institute of Technology
Partnership includes Hyundai Motor North America donating four NEXO fuel cell electric SUVs and Hyundai Motor Group donating a hydrogen electrolyzer project exclusively for campus use
New initiative brings NEXO hydrogen fuel cell SUVs and fueling infrastructure to campus, advancing research, workforce development, and zero-emissions logistics
The NEXO SUVs will support both campus operations and interdisciplinary research across engineering, sustainability, energy systems, and public policy
Apr 29 · 16:40·Hyundai Motor Company